The Translator program is funded through the Cures Acceleration Network (CAN). CAN is designed to advance the development of high-need cures and reduce significant barriers between research discovery and clinical trials. Learn more about the Biomedical Data Translator program.
-
Research
-
-
Funding & Notices
-
-
News & Media
-
About Translation
-
-
About NCATS
-
NCATS Programs & Initiatives
- 3-D Tissue Bioprinting Program
- A Specialized Platform for Innovative Research Exploration (ASPIRE)
- Assay Development and Screening Technology (ADST)
- Biomedical Data Translator
- Bridging Interventional Development Gaps (BrIDGs)
- Chemistry Technology
- Discovering New Therapeutic Uses for Existing Molecules
- Genetic and Rare Diseases Information Center (GARD)
- Matrix Combination Screening
- NCATS Chemical Genomics Center (NCGC)
- NIH Common Fund Programs
- Pfizer's Centers for Therapeutic Innovation (CTI) for NIH Researchers
- Rare Diseases Registry Program (RaDaR)
- Tissue Chip for Drug Screening
- Toxicology in the 21st Century (Tox21)
- Trans-NIH RNAi Facility (TNRF)
- Therapeutics for Rare and Neglected Diseases (TRND)
-